NCT02198443View on ClinicalTrials.gov

Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

June 6, 2015

Primary Completion Date

July 15, 2016

Conditions
HIV
Interventions
DRUG

Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)

(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets

DRUG

elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil

Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.

Trial Locations (1)

08036

Hospital clínico y provincial de Barcelona, Barcelona

All Listed Sponsors
lead

Fundacion Clinic per a la Recerca Biomédica

OTHER

NCT02198443 - Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. | Biotech Hunter | Biotech Hunter